Pasireotide Diaspartate Drug Asset Due Diligence Report 2026

This Pasireotide Diaspartate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

100

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pasireotide Diaspartate can convert its Synthetic peptide, Cyclic Peptide profile and SSTR1 x SSTR2 x SSTR3 x SSTR5 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pasireotide Diaspartate (query alias: pasireotide)
Modality / target	Synthetic peptide, Cyclic Peptide; SSTR1 x SSTR2 x SSTR3 x SSTR5; SSTR1 agonists, SSTR2 agonists, SSTR3 agonists
Highest global status	Approved
Originator	Novartis Pharma AG
Active developers	Recordati Rare Diseases, Inc., Recordati Rare Diseases, Novartis Pharmaceuticals Canada, Inc.

The MCP disease footprint includes Gigantism, Growth Hormone Excess, Cushing Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06784752	Phase 3	Recruiting	240	Progression Free Survival (PFS) centrally assessed by Blinded Independent Review Committee (BIRC)
NCT06456359	Phase 2	Recruiting	28	progression-free survival (PFS)
NCT06295952	Phase 2	Recruiting	10	biochemical response rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment

Phase 4; n=337; evaluation: not stated. Reported fields: -; -; AEs : All grades = 265 participants

Long-Term Effect of Subcutaneous Pasireotide on Clinical and Quality of Life Endpoints in Patients with Cushing's Disease: Results from a Non-interventional Study

Phase 3; n=152; evaluation: Positive. Reported fields: Body weight = 79 kg ( 41 - 152); Body weight = 84 kg ( 49 - 141)

THU066 An 8-year Interim Report Of The B2412 Study, An Open-label, Multicenter Pasireotide Rollover Study For Patients Who Continued To Receive Benefit From Pasireotide At Completion Of An Earlier Trial

Phase 4; n=341; evaluation: Positive. Reported fields: AE frequency = 26.1 % ; AE frequency = 26.1 % ; AE frequency = 26.1 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pasireotide Diaspartate addresses Gigantism, Growth Hormone Excess, Cushing Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-10-25	维健医药与Recordati AG就Signifor® LAR（长效帕瑞肽）产品达成战略合作协议	Approved	Financial terms not disclosed
2019-07-12	RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699)	Approved	US$390.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Synthesis method of pasireotide intermediate”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO